p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32) Journal Article
| Authors: | Louie, D. C.; Offit, K.; Jaslow, R.; Parsa, N. Z.; Murty, V. V. V. S.; Schluger, A.; Chaganti, R. S. K. |
| Article Title: | p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32) |
| Abstract: | The t(11;14)(q13;q32) translocation, which juxtaposes the BCL1 oncogene with the Ig heavy chain locus, has been associated with an uncommon subtype of non-Hodgkin's lymphoma (NHL) termed mantle cell lymphoma (MCL). To date, no molecular marker that serves as an indicator of tumor progression or clinical prognosis has been described for NHLs with this translocation. We examined a panel of NHLs with t(11;14) for overexpression of p53 and correlated the results with single-strand conformation polymorphism (SSCP) analysis, karyotypic features, and clinical course. NHLs with t(11;14) were identified from 30 patients. The diagnosis was MCL for 23 of 30, small lymphocytic lymphoma for 4 of 30, and diffuse large-cell lymphoma for 3 of 30 cases. The results of immunohistochemistry analysis using a monoclonal anti-p53 antibody on paraffin-embedded specimens were compared with the SSCP data, the tumor karyotypes, and clinical course of each patient. DNA sequencing of exons was performed on cases that showed conformational changes by SSCP analysis. NHLs from 5 of 23 patients with MCL were positive for p53 overexpression. Deletions of chromosome 17p were identified in 2 of 30 cases, both of which were MCLs showing p53 overexpression. Two of the five MCLs with p53 overexpression showed evidence for TP53 mutations. None of the 18 MCLs negative for p53 overexpression showed conformational changes by SSCP. For these 18 patients with MCLs that did not overexpress p53, the median survival was 63 months, compared with 12 months for the 5 patients with MCLs positive for p53 overexpression (P < .001). These results suggest that p53 overexpression in MCL with t(11;14)(q13;q32) may serve as a marker of poor prognosis. (C) 1995 by The American Society of Hematology. |
| Keywords: | protein; cytogenetic analysis; mutations; tumor-suppressor gene; non-hodgkins-lymphomas; centrocytic lymphoma; consecutively ascertained specimens; clinical correlations; intermediate lymphocytic lymphoma; zone lymphoma |
| Journal Title: | Blood |
| Volume: | 86 |
| Issue: | 8 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 1995-10-18 |
| Start Page: | 2892 |
| End Page: | 2899 |
| Language: | English |
| ACCESSION: | WOS:A1995RZ07100003 |
| PROVIDER: | wos |
| PUBMED: | 7579380 |
| DOI: | 10.1182/blood.V86.8.2892.2892 |
| Notes: | Note -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work